On Wednesday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s shares inclined 3.63% to $232.18.
Biotech company Pharming Group N.V. published its (unaudited) financial report for the six months ended 30 June 2015.
FINANCIAL HIGHLIGHTS
- Revenues from operations raised to €5.2 million (H1 2014: €2.5 million) as a result of substantially raised revenues from product sales of €4.1 million (€2.9 million for Q2), contrast to €1.4 million for H1 2014. Revenues from Ruconest® sales in the US amounted to €3.0 million (€2.4 million for Q2) and in the EU amounted to €1.1 million (€0.5 million for Q2).
- Gross profit raised to €2.9 million (€2.1 million for Q2) from €0.7 million in H1 2014 as a result of sales in the US and a gain on inventory impairments, reflecting the improving yields from sales in the US and direct commercialisation in the EU.
- As result of increasing costs of operations (R&D, General and Administrative and Marketing and Sales), operating result reduced by €0.7 million, to a loss of €6.1 million contrast to a €5.4 million loss for H1 2014. The enhance is mostly a result of the (non-cash) share-based compensation.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Scorpio Tankers Inc.(NYSE:STNG)’s shares showed no change to $9.27.
Scorpio Tankers Inc. (NYSE: STNG) (the “Company”) declared recently an update on its Securities Repurchase Program and delivery of two LR2 product tankers.
$250 Million Securities Repurchase Program
So far during the month of August 2015, the Company has purchased 1,716,155 of its common shares in the open market at an average price of $10.48 per share.
Since the $250 Million Securities Repurchase Program was authorized by the Company’s Board of Directors at the end of May 2015, the Company has attained the following:
- an aggregate of 1,986,504 of its common shares at an average price of $10.42 per share.
- $1.5 million face value of its Convertible Senior Notes Due 2019 at an average price of $1,088.10 per $1,000 principal amount.
The Company has $227.6 million remaining under its securities buyback program as of the date of this press release. The attained common shares are being held as treasury shares. The Company anticipates to repurchase any securities in the open market, at times and prices that are considered to be appropriate by the Company, but is not obligated under the terms of the program to repurchase any securities.
Scorpio Tankers Inc., together with its auxiliaries, engages in the seaborne transportation of refined petroleum products and crude oil worldwide. As of July 13, 2015, it owned 67 tankers comprising 16 LR2 tankers, 15 Handymax tankers, and 45 MR tankers with an average age of 0.9 years; and time charters-in 17 product tankers, counting 4 LR2, 4 LR1, 4 MR, and 5 Handymax tankers. The company was founded in 2009 and is based in Monaco, Monaco.
At the end of Wednesday’s trade, U.S. Silica Holdings Inc (NYSE:SLCA)‘s shares dipped -2.77% to $18.96.
U.S. Silica Holdings, Inc. (SLCA) declared that its Board of Directors has declared a quarterly cash dividend of $0.125 per common share. The dividend is payable on Oct. 2, 2015 for all shareholders of record as of the close of business on Sept. 15, 2015.
U.S. Silica Holdings, Inc. produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The company offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
RR Donnelley & Sons Co (NASDAQ:RRD), ended its Wednesday’s trading session with 1.19% gain, and closed at $15.27.
RR Donnelley & Sons Company (RRD) recently declared that it intends to create three independent, publicly traded companies: one business focused on financial communications and data services; one business focused on publishing and retail-centric print services; and one business focused on customized multichannel communications administration.
Planned Benefits
- Each business to focus on its distinct planned preceding ties, driving opportunities to accelerate growth and enhance long-term value.
- Greater flexibility to execute tailored business strategies and compete in evolving markets.
- Even more focused brand strategy to support each business’s marketing plan.
R.R. Donnelley & Sons Company provides integrated communications solutions to private and public sector clients in the United States and internationally. The company operates through Publishing and Retail Services, Variable Print, Planned Services, and International segments. Its product and service offerings comprise magazines, catalogs, retail inserts, books, directories, and packaging products; commercial and digital print, direct mail, office products, labels, statement printing, and forms; and logistics services, financial print products and related services, print administration products, and digital and creative solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
